Approval supported by data from phase III confirmatory trials, VIALE-A and VIALE-C VIALE-A study showed Venclexta plus azacitidine significantly improved overall survival in newly diagnosed AML compared to azacitidine alone Supplemental New Drug Applications approved under the FDA’s Real-Time Oncology Review pilot programme and Project Orbis initiative Basel, 19 October 2020 – Roche (SIX: RO,... Read more
Dr. Peter O’Toole from the University of York (United Kingdom) has started a podcast series to better understand not only what drives great scientists but also to learn what really inspires them and what they enjoy most in life. We spoke with Dr. O’Toole about his background and his thoughts for this podcast series. Tell... Read more
WALTHAM, Mass.–(BUSINESS WIRE)–Oct. 12, 2020– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates reported and organic revenue growth of approximately 35% and 33%, respectively, for the third quarter ended October 4, 2020. The strong revenue growth performance was driven by continued better-than-expected demand for PerkinElmer’s... Read more
WALTHAM, Mass.–(BUSINESS WIRE)–Oct. 12, 2020– The table in the release was incorrect. The corrected table should read: PerkinElmer, Inc: PerkinElmer, Inc. and SubsidiariesRECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1) PKI Three Months Ended October 4, 2020 Organic revenue growth: Reported revenue growth 35% Less: effect of foreign exchange rates 1% Less: effect... Read more
AUSTIN, Texas, Oct. 7, 2020 /PRNewswire/ — Luminex Corporation (Nasdaq: LMNX) today announced 3rd quarter 2020 revenues of approximately $106 million, up approximately 35% over the 3rd quarter of 2019. Highlights include: Molecular Diagnostics revenue of approximately $60 million, up almost 100% vs. Q3 2019 Licensed Technologies Group revenue of approximately $35 million, down 10% vs.... Read more
Company’s Informatics Solutions Meet AICPA’s Trust Service Principles for Security, Confidentiality & Availability WALTHAM, Mass. – September 30, 2020 – PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that the PerkinElmer Signals™ Notebook and PerkinElmer Signals™ Medical Review SaaS solutions have been granted SOC 2 Level 1 Attestation for... Read more
RT-PCR Newborn Screening Assay for SMA, SCID and XLA to be Integrated into Company’s Sample-to-Result Workflow WALTHAM, Mass. – September 30, 2020 – PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that the Company’s EONIS™ screening assay for newborns that simultaneously tests for SMA (spinal muscular atrophy), SCID (severe... Read more
Smart utility network to help tackle projected water shortages RYE BROOK, N.Y.–(BUSINESS WIRE)–Sep. 29, 2020– Xylem Inc. (NYSE: XYL), a leading global water technology company, is helping to prevent water shortages in the U.K. as part of its commitment to address scarcity and to make communities more sustainable and resilient. Xylem’s recently published 2019 Sustainability... Read more
SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the third quarter 2020 following the close of market on Thursday, October 29, 2020. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, President and Chief Executive Officer, and Sam Samad, Chief Financial Officer, will host... Read more
The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. The test targets antibodies against the spike protein. This is the focus of vaccines in development and convalescent plasma therapy.1 Using the Elecsys Anti-SARS-COV-2 S antibody test, together with the Elecsys... Read more